Aslan Pharmaceuticals Pte Ltd-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Aslan Pharmaceuticals Pte Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8011889
◆発行会社(調査会社):GlobalData
◆発行日:2017年12月13日
◆ページ数:48
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:シンガポール
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Aslan Pharmaceuticals Pte Ltd (Aslan), a subsidiary of Aslan Pharmaceuticals Ltd is a biotechnology company that offers immuno-oncology agents and targeted therapies. The company’s pipeline products comprise varlitinib, ASLAN002, ASLAN003 and ASLAN004. Its ASLAN002 is a small molecule inhibitor of RON and cMET receptor tyrosine kinases for the treatment of gastric and breast cancer. Aslan’s ASLAN003 is a small molecule inhibitor of dihydroorotate dehydrogenase inhibitor to treat tumors; and ASLAN004 is a full human monoclonal antibody that reduces exacerbation in moderate or severe asthma and improves the functioning of lungs. It operates in Singapore, Taiwan, China and Australia. Aslan is headquartered in Singapore.

Aslan Pharmaceuticals Pte Ltd – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Aslan Pharmaceuticals Pte Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Aslan Pharmaceuticals Pte Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Aslan Pharmaceuticals Pte Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Aslan Pharmaceuticals Pte Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Aslan Pharmaceuticals Pte Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Aslan Pharmaceuticals Pte Ltd, Pharmaceuticals & Healthcare, Deal Details 13
Venture Financing 13
Aslan Pharma Raises USD23 Million in Venture Financing 13
Aslan Pharma Raises Additional USD9 Million in Venture Financing 15
Aslan Pharma Raises USD34 Million in Series C Financing 17
Aslan Pharma Raises US$22 Million In Series B Financing 19
Aslan Pharma Raises US$12 Million In Series A Financing 21
Partnerships 22
Aslan Pharma Enters into Agreeement with Cancer Science Institute Of Singapore and National University Cancer Institute 22
Aslan Pharma Enters into MoU with National Cancer Centre Singapore 23
ASLAN Pharma Enters into Agreement with ACT Genomics 24
Licensing Agreements 25
ASLAN Pharma Enters into Licensing Agreement with Nanyang Technological University 25
ASLAN Pharma Enters into Licensing Agreement with Agency for Science, Technology and Research 26
Hyundai Pharma Enters into Licensing Agreement with Aslan Pharma 27
Aslan Pharma Enters Into Licensing Agreement With CSL For CSL-334 28
Aslan Pharma Expands Licensing Agreement with Almirall for LAS186323 29
Array BioPharma Enters Into Licensing Agreement With ASLAN Pharma For ARRY-543 30
Equity Offering 31
Aslan Pharma Plans to Raise USD84 Million in Public Offering of Shares 31
Aslan Pharma Plans to Raise Funds through Private Placement of Shares 32
Aslan Pharma Raises USD33.2 Million in IPO 33
Aslan Pharmaceuticals Pte Ltd – Key Competitors 34
Aslan Pharmaceuticals Pte Ltd – Key Employees 35
Aslan Pharmaceuticals Pte Ltd – Locations And Subsidiaries 36
Head Office 36
Other Locations & Subsidiaries 36
Recent Developments 37
Corporate Communications 37
Jan 23, 2017: Aslan Pharmaceuticals Receives Approval To List On Taipei Exchange 37
May 30, 2016: ASLAN Pharmaceuticals appoints three new Non-Executive Directors 38
Feb 29, 2016: Aslan Pharmaceuticals Appoints Andrew Howden As Independent Director 39
Product News 40
04/21/2016: New Data On Aslan’s Varlitinib To Be Published At 2016 Annual Meeting Of American Society Of Cancer Oncology 40
02/23/2016: Aslan Pharmaceuticals To Present New Data On Varlitinib At Annual American Association For Cancer Research Meeting 41
01/24/2017: Aslan Pharmaceuticals To Present At The Cholangiocarcinoma Foundation Annual Conference 2017 42
Product Approvals 43
Feb 19, 2017: ASLAN Pharmaceuticals receives Orphan Drug Designation in Korea for varlitinib (ASLAN001) in biliary tract cancer 43
Jun 24, 2016: ASLAN receives Orphan Drug Designation for varlitinib in gastric cancer 44
Clinical Trials 45
Jun 07, 2017: Aslan Pharmaceuticals Announces New Positive Data Identifying ASLAN003 As A Novel Therapeutic Agent In Acute Myeloid Leukaemia 45
Feb 13, 2017: Aslan Pharmaceuticals Announces First Patient Enrolled In Phase 1 Study Of Varlitinib In Japan 46
Feb 09, 2017: ASLAN Pharmaceuticals reports positive top-line results for phase 2 clinical trial of varlitinib in metastatic breast cancer 47
Appendix 48
Methodology 48
About GlobalData 48
Contact Us 48
Disclaimer 48

List of Tables
Aslan Pharmaceuticals Pte Ltd, Pharmaceuticals & Healthcare, Key Facts 2
Aslan Pharmaceuticals Pte Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Aslan Pharmaceuticals Pte Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Aslan Pharmaceuticals Pte Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Aslan Pharmaceuticals Pte Ltd, Deals By Therapy Area, 2011 to YTD 2017 9
Aslan Pharmaceuticals Pte Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Aslan Pharma Raises USD23 Million in Venture Financing 13
Aslan Pharma Raises Additional USD9 Million in Venture Financing 15
Aslan Pharma Raises USD34 Million in Series C Financing 17
Aslan Pharma Raises US$22 Million In Series B Financing 19
Aslan Pharma Raises US$12 Million In Series A Financing 21
Aslan Pharma Enters into Agreeement with Cancer Science Institute Of Singapore and National University Cancer Institute 22
Aslan Pharma Enters into MoU with National Cancer Centre Singapore 23
ASLAN Pharma Enters into Agreement with ACT Genomics 24
ASLAN Pharma Enters into Licensing Agreement with Nanyang Technological University 25
ASLAN Pharma Enters into Licensing Agreement with Agency for Science, Technology and Research 26
Hyundai Pharma Enters into Licensing Agreement with Aslan Pharma 27
Aslan Pharma Enters Into Licensing Agreement With CSL For CSL-334 28
Aslan Pharma Expands Licensing Agreement with Almirall for LAS186323 29
Array BioPharma Enters Into Licensing Agreement With ASLAN Pharma For ARRY-543 30
Aslan Pharma Plans to Raise USD84 Million in Public Offering of Shares 31
Aslan Pharma Plans to Raise Funds through Private Placement of Shares 32
Aslan Pharma Raises USD33.2 Million in IPO 33
Aslan Pharmaceuticals Pte Ltd, Key Competitors 34
Aslan Pharmaceuticals Pte Ltd, Key Employees 35
Aslan Pharmaceuticals Pte Ltd, Other Locations 36
Aslan Pharmaceuticals Pte Ltd, Subsidiaries 36

★海外企業調査レポート[Aslan Pharmaceuticals Pte Ltd-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Sinclair Oil Corporation:企業の戦略・SWOT・財務分析
    Sinclair Oil Corporation - Strategy, SWOT and Corporate Finance Report Summary Sinclair Oil Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Rinnai Corp (5947):企業の財務・戦略的SWOT分析
    Rinnai Corp (5947) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Sulzer Ltd (SUN):企業の財務・戦略的SWOT分析
    Sulzer Ltd (SUN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Oman Air (SAOC):企業の戦略・SWOT・財務分析
    Oman Air (SAOC) - Strategy, SWOT and Corporate Finance Report Summary Oman Air (SAOC) - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Arkansas Electric Cooperative Corporation:企業の戦略的SWOT分析
    Arkansas Electric Cooperative Corporation - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and …
  • Rawson Oil & Gas Ltd (RAW):石油・ガス:M&Aディール及び事業提携情報
    Summary Rawson Oil & Gas Ltd (Rawson), formerly Rawson Resources Ltd, is an oil and gas company that explores and develops crude hydrocarbon properties. The company’s projects include Cooper Basin, Otway Basin, Surat Basin, PEL154 and PEL155, Taranaki Basin, Cape Vogel Basin, North New Guinea Basin, …
  • University of Sheffield:製薬・医療:M&Aディール及び事業提携情報
    Summary University of Sheffield (Sheffield University) is an educational service provider that offers undergraduate, postgraduate, research and certificate programmes. The university offers courses in various fields including arts and humanities, engineering, medicine, dentistry and health; social s …
  • Old Dominion Freight Line Inc (ODFL):企業の財務・戦略的SWOT分析
    Old Dominion Freight Line Inc (ODFL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Grant Thornton International Ltd:企業の戦略的SWOT分析
    Grant Thornton International Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major pr …
  • Ferndale Pharma Group Inc-製薬・医療分野:企業M&A・提携分析
    Summary Ferndale Pharma Group Inc (Ferndale Pharma), formerly Ferndale Laboratories Inc is a manufacturer and distributor of pharmaceutical products. The company provides surgical instruments, medical supplies, skin care products, topical therapeutic products, prescription, over the counter products …
  • Celltrion Inc (068270):企業の財務・戦略的SWOT分析
    Celltrion Inc (068270) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Hochdorf Holding AG (HOCN):企業の財務・戦略的SWOT分析
    Hochdorf Holding AG (HOCN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Murree Brewery Co. Ltd.:企業の戦略・SWOT・財務情報
    Murree Brewery Co. Ltd. - Strategy, SWOT and Corporate Finance Report Summary Murree Brewery Co. Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Epuron Pty Ltd:電力:M&Aディール及び事業提携情報
    Summary Epuron Pty Ltd (Epuron), formerly Taurus Energy Pty Ltd, a subsidiary of Epuron Holding GmbH & Co KG, is a renewable energy company that develops wind and solar energy projects. The company provides resource monitoring and assessment for wind and solar energy projects including data capture …
  • John Keells Hotels Plc:企業の戦略・SWOT・財務分析
    John Keells Hotels Plc - Strategy, SWOT and Corporate Finance Report Summary John Keells Hotels Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Mitsubishi Corporation (8058):電力:M&Aディール及び事業提携情報
    Summary Mitsubishi Corporation (Mitsubishi) is an integrated company that develops and operates businesses across industry including industrial finance, energy, metals, machinery, chemicals, living essentials, and environmental business. The company manufactures and markets a wide range of products, …
  • Hotel Croatia Cavtat:企業の戦略・SWOT・財務分析
    Hotel Croatia Cavtat - Strategy, SWOT and Corporate Finance Report Summary Hotel Croatia Cavtat - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • StealthGas Inc (GASS):企業の財務・戦略的SWOT分析
    Summary StealthGas Inc (StealthGas) is an oil and gas shipping company that offers seaborne and oil and gas transportation services. The company provides transportation of petroleum and petrochemical gas products in liquefied forms. StealthGas transports byproducts of crude oil and natural gas inclu …
  • AptarGroup Inc:企業の戦略・SWOT・財務情報
    AptarGroup Inc - Strategy, SWOT and Corporate Finance Report Summary AptarGroup Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Mead Johnson Nutrition Co:企業の戦略的SWOT分析
    Mead Johnson Nutrition Co - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆